Neovasc (NVCN) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVCN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCN, but not buy additional shares or sell existing shares.
View NVCN analyst ratings or view top-rated stocks.

Neovasc Inc. (NASDAQ:NVCN) announced its quarterly earnings results on Friday, March, 31st. The medical equipment provider reported ($5.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.93) by $3.11. The medical equipment provider earned $1.45 million during the quarter, compared to the consensus estimate of $0.90 million. Neovasc had a negative trailing twelve-month return on equity of 127.25% and a negative net margin of 1,082.92%.

Shares of Neovasc reverse split on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Black Maple Capital Management LP (3.93%), Yakira Capital Management Inc. (1.37%), MMCAP International Inc. SPC (1.01%), Sio Capital Management LLC (0.82%), Quinn Opportunity Partners LLC (0.73%) and Renaissance Technologies LLC (0.64%).

One share of NVCN stock can currently be purchased for approximately $30.03.

Neovasc (NASDAQ:NVCN) has a market capitalization of $82.28 million and generates $3.81 million in revenue each year. The medical equipment provider earns $-41,200,000.00 in net income (profit) each year or ($15.08) on an earnings per share basis.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for the company is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384.